FY2024 EPS Estimates for Humacyte Cut by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at Cantor Fitzgerald reduced their FY2024 EPS estimates for shares of Humacyte in a research note issued to investors on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of ($1.41) per share for the year, down from their previous forecast of ($1.23). Cantor Fitzgerald has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.18) per share.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

Several other equities research analysts have also recently commented on HUMA. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a report on Monday, September 9th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Humacyte in a report on Wednesday. Benchmark reissued a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Finally, Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $11.00.

Humacyte Stock Down 0.4 %

HUMA opened at $5.34 on Thursday. The company’s 50 day simple moving average is $5.45 and its two-hundred day simple moving average is $6.18. Humacyte has a 1-year low of $2.25 and a 1-year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41.

Insider Transactions at Humacyte

In related news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathleen Sebelius sold 5,182 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the sale, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,084,153 shares of company stock worth $6,869,996. 11.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Several large investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of Humacyte in the second quarter worth $28,000. Concurrent Investment Advisors LLC acquired a new position in Humacyte during the 3rd quarter worth $75,000. Principal Financial Group Inc. acquired a new position in shares of Humacyte during the second quarter worth about $83,000. FORA Capital LLC purchased a new stake in shares of Humacyte in the 3rd quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new stake in Humacyte in the second quarter valued at $97,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.